Group 1 - The U.S. Food and Drug Administration (FDA) has declined to approve Aldeyra Therapeutics' drug for a specific type of eye disease [1] - This decision represents a setback for Aldeyra Therapeutics, which was seeking approval for its treatment [1] Group 2 - The FDA's rejection may impact Aldeyra's stock performance and investor sentiment [1]